The Alfred E. Mann Foundation for Scientific Research (AMF) today announced the sale of intellectual property to Medtronic (NYSE:MDT).
As part of the transaction of IP related to implanted infusion pumps, AMF will work with Medtronic to develop the technology into a next-generation implantable insulin pump for people living with hard-to-treat type 1 diabetes in Europe.
Get the full story at our sister site, Drug Delivery Business News.
Making medical devices: Everything you need to know
The innovation-fueled evolution of drug eluting stents
Dexcom CEO Kevin Sayer says G7 will be ‘wonderful’
Getting the inside scoop behind top medtech innovationsAutumn is upon us, and it is once again time to sip a pumpkin spice latte — or a pumpkin beer — and crack open our latest Medical Device Handbook.
Once again, we’ve reached out to experts across the industry to curate dozens of “what is” and “how to” types of articles that cover a breadth of categories: components, drug delivery, manufacturing and machining, materials, product design and development, regulatory, software, sterilization services and tubing.
As the years go by, I’m proud that we’re including more insights from the major medical device companies in each succeeding issue. This time around, we spoke to experts involved in some of the major industry innovations of the past decade:
Now VP of R&D …Medtronic CFO Karen Parkhill has been named as an outstanding finance executive by the Minneapolis/St. Paul Business Journal in Minnesota.
Parkhill is one of 14 individuals who will be honored in the newspaper’s 2021 CFO of the Year awards in November. She was one of two winners in the public company category, joined by Piper Sandler Cos. CFO Tim Carter.
Parkhill joined Fridley, Minnesota-based Medtronic (NYSE:MDT) in 2016. She was previously CFO and vice chair of Comerica.
In addition to leading Medtronic’s global finance organization and supporting functions (treasury, controller, tax, internal audit, investor relations, corporate strategy and business development), Parkhill also leads IT and the enterprise excellence restructuring program.
Medtronic (NYSE:MDT) announced that it picked up three victories in an intellectual property (IP) dispute against Axonics (NSDQ:AXNX) over sacral neuromodulation devices.
According to a news release, the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) rejected Axonics’ attempt to invalidate three Medtronic patents in its IP infringement lawsuit related to Medtronic’s InterStim neuromodulation device family. Nearly one year ago, the PTAB handed down a decision to reject one of Axonics’ claims to invalidate a Medtronic patent and has now added three more.
Get the full story at our sister site, MassDevice.
Judge Edgardo Ramos of the U.S. District Court of Southern New York, in a Sept. 10 order, ruled that the agreement between Walland and Medtronic was covered by the law in California, where Walland has resided the majority of the time in recent years, and not New York.
Under California law, “every contract by which anyone is restrained from engaging in a lawful profession, trade, or business of any kind is to that extent void,” Ramos wrote.
“An injunction would impose a hardship on Walland because it would bar him from his current employment, and given Medicrea’s nationwide market, he would likely be barred from working anywhere else in the country that overlaps with his specialty,” Ramos said. “Further, if enjoined, Walland will be deprived of the benefits of C…
Medtronic (NYSE:MDT) announced that it picked up three victories in an intellectual property (IP) dispute against Axonics (NSDQ:AXNX) over sacral neuromodulation devices.
According to a news release, the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) rejected Axonics’ attempt to invalidate three Medtronic patents in its IP infringement lawsuit related to Medtronic’s InterStim neuromodulation device family. Nearly one year ago, the PTAB handed down a decision to reject one of Axonics’ claims to invalidate a Medtronic patent and has now added three more.
Axonics develops the r-SNM sacral neuromodulation system, which it touts as the first of its kind approved for sale in the U.S., Europe, Canada and Australia and the only SNM device approved for full-body MRI scans without needing the device explanted.
The company, a direct competitor of Medtronic in the space, has rivaled the medtech giant with multiple regulator…
The highly anticipated results will offer new insight into the Fridley, Minnesota-based medical device manufacturer’s quest to build a billion-dollar business treating hypertension. CEO Geoff Martha recently reported “good progress” in those efforts, saying the trial “represents the final piece of a large body of evidence that we intend to submit to the FDA for approval.”
Get the full story at our sister site, Medical Design & Outsourcing.
Medtronic’s Symplicity Spyral renal denervation system delivers energy to the nerves leading to the kidneys, which help regulate blood pressure. [Image courtesy of Medtronic]
Medtronic’s clinical study of its Symplicity Spyral renal denervation system for hypertension is likely to go down to the wire for inclusion as a late-breaking clinical trial at the upcoming Transcatheter Cardiovascular Therapeutics (TCT) conference.The highly anticipated results will offer new insight into the Fridley, Minnesota-based medical device manufacturer’s quest to build a billion-dollar business treating hypertension. CEO Geoff Martha recently reported “good progress” in those efforts, saying the trial “represents the final piece of a large body of evidence that we intend to submit to the FDA for approval.”
Medtronic (NYSE:MDT) said it still hopes to present results of its Spyral HTN-ON MED trial at the Cardiovascul…
Corin Group announced today that it appointed former Medtronic executive Jacob Paul as its new CEO.
Cirencester, UK-based Corin Group said in a news release that Corin “brings unparalleled strategic and operational experience” to the company and is “well placed” to lead it through the next phase of its mission to improve patient activity and wellbeing with implants and connected technologies.
Paul most recently served as SVP and president of Medtronic’s cranial and spinal technologies segment, growing the medtech giant’s business with technologies including robotics, navigation, imaging and AI-driven surgical planning.
“I am very pleased and proud to welcome Jacob to Corin,” Corin interim CEO & non-executive chairman of the board David Floyd said in the release. “His appointment will be pivotal in driving the innovation and expansion of our successful orthopaedic business into the rapidly evolving and g…
(Image courtesy of the University of Minnesota)
The University of Minnesota and medical device manufacturers have partnered to launch an organization for cybersecurity research, outreach and workforce training.
Medtronic (NYSE:MDT) , Boston Scientific (NYSE: BSX), Abbott Laboratories (NYSE:ABT) , Smiths Medical and UnitedHealth Group’s (NYSE: UNH) Optum contributed financial support as founding partners of the University of Minnesota Center for Medical Device Cybersecurity.
The Center for Medical Device Cybersecurity will be part of the College of Science and Engineering’s Technological Leadership Institute and also collaborate with the Earl E. Bakken Medical Devices Center and the University of Minnesota’s Office of the Vice President for Research. The center will host roundtables, a hackathon, industry networking, training and offer summer internships and a medical device cybersecurity short cours…
Medtronic (NYSE:MDT) reported new clinical data from its Navablate study of bronchoscopic microwave ablation with its Emprint ablation catheter kit to treat malignant lung nodules.
“Patients with malignant lesions in the lung often have limited therapy options due to lesion locations, comorbidities and treatment side effects,” said one of the principal investigators, Kelvin Lau — consultant thoracic surgeon at St. Bartholomew’s Hospital in London — in a news release. “The results from the Navablate study explore the potential benefit of a more individualized treatment for patients and offer a new option for surgeons and physicians to provide a minimally invasive, localized treatment of malignant lesions in the lung.”
Surgeons in the United Kingdom and Hong Kong performed bronchoscopic ablation on 30 patients using Medtronic’s Emprint ablation catheter kit and the device maker’s electromagnetic navigation bronchoscopy system. Invest…
Medtronic’s (NYSE:MDT) India-based subsidiary announced a strategic partnership with Stasis Health and its bedside monitoring system.
India Medtronic Private Limited and Stasis Health (a wholly-owned subsidiary of Stasis Labs) partnered to scale up and expand access to the Stasis Monitor, a connected care bedside multi-parameter monitoring system, according to a news release.
The Stasis Monitor, which uses patented predictive artificial intelligence, holds FDA clearance for automating and digitizing monitoring, documentation and communication of critical patient information. Medtronic believes the addition of the platform to its portfolio expands its ability to serve patients inside the hospital while offering physicians the option to remotely monitor their patients.
Available for use in emergency ICUs, surgical ICUs, high-dependency units, step-down units and private patient rooms, the Stasis Monitor system includes a bedside monitor that monitors…